O Orexo AB
O
Închisă
18.26 1.33
Rezumat
Modificarea prețului
24h
Minim
17.96
Maxim
18.28
Venit | 41M -75M |
|---|---|
Vânzări | 1.7M 5M |
EPS | 20.884 |
Marjă de profit | -1,500 |
Angajați | 65 |
EBITDA | 206M -66M |
Următoarele câștiguri | 16 iul. 2026 |
|---|
Capitalizare de piață | -50M 650M |
|---|---|
Deschiderea anterioară | 16.93 |
Închiderea anterioară | 18.26 |
Orexo AB Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Orexo AB Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
